Byondis (NASDAQ: BYDIF) Names Christoph Korpus as CEO
Key Developments Byondis (NASDAQ: BYDIF), a biopharmaceutical company focused on innovative cancer therapies, has announced the appointment of Dr. Christoph Korpus, PhD, MBA, as the new Chief Executive Officer effective immediately. Christoph previously served as Chief Business Officer since January 2025 and will now succeed founder and former CEO Dr. Jacques Lemmens, who will remain with Byondis as Chairman of the Board. Under Dr. Korpus’ leadership, Byondis will enhance development…
